Introduction:
Sunitinib is an oral antiangiogenic drug with anti-Vascularendothelial growth factor (VEGF) properties. It is used to treat renal cell carcinoma, pancreatic neuroendocrine tumours, and gastrointestinal stromal tumours (1)Treatment with anti-VEGF antibody medication improves the survival of patients with colorectal carcinoma (2, 3) and clear metastatic cell renal cell carcinoma (4).
Sunitinib-induced thrombotic microangiopathy (TMA) is a secondary TMA caused by sunitinib. Despite the extensive use of sunitinib in patients with renal cell carcinoma and other malignancies, little is known about this complication of sunitinib. No clinical trials of sunitinib have studied this complication in any group of patients.
TMA is characterised by microangiopathic hemolytic anemia (MAHA), thrombocytopenia, and various organ dysfunction (5). Multiple case reports of sunitinib-induced TMA have been published(6-11). In this study, we report another case of sunitinib induced TMA and discuss clinical and laboratory manifemanifestationis causes and pathogenesis of the disease.